Interestingly, despite the individual ameliorative effects of Memantine and TBB, this combined treatment significantly increased AD-tau burden compared to non-pharmacologically treated ADPHF neurons (Fig. 7f). The gene discussed is MAPT; the disease is Alzheimer disease.